Publications by authors named "Julia Maltzman"

Claim this Profile
A
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.
Manish A Shah, Alexander Starodub, Sunil Sharma, Jordan Berlin, Manish Patel, Julia D Maltzman

Clin Cancer Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Claire N Harrison, Alessandro M Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, Julia D Maltzman

Lancet Haematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Ruben A Mesa, Jean-Jacques Kiladjian, John V Catalano, Timothy Devos, Miklos Egyed, Julia D Maltzman

J Clin Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.
Srdan Verstovsek, Stephane Courby, Martin Griesshammer, Ruben A Mesa, Carrie Baker Brachmann, Julia D Maltzman

Leuk Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
Srdan Verstovsek, Michael R Savona, Ruben A Mesa, Hua Dong, Julia D Maltzman

Br J Haematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
Anubha Gupta, Ziad Hussein, Raffit Hassan, Jason Wustner, Julia D Maltzman

Cancer Chemother Pharmacol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folate receptor-α (FOLR1) expression and function in triple negative tumors.
Brian M Necela, Jennifer A Crozier, Cathy A Andorfer, Laura Lewis-Tuffin, Jennifer M Kachergus, Julia D Maltzman

PLoS One· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors.
Brian M Necela, Jennifer A Crozier, Cathy A Andorfer, Laura Lewis-Tuffin, Jennifer M Kachergus, Julia D Maltzman

PLoS One· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.
Liza Lindenberg, Anish Thomas, Stephen Adler, Esther Mena, Karen Kurdziel, Julia Maltzman

Oncotarget· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Raffit Hassan, Hedy L Kindler, Thierry Jahan, Lyudmila Bazhenova, Martin Reck, Julia D Maltzman

Clin Cancer Res· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.
Daniel C Christoph, Bernadette Reyna-Asuncion, Biftu Hassan, Cindy Tran, Julia D Maltzman

Clin Lung Cancer· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease.
Daniel J O'Shannessy, Elizabeth B Somers, Julia Maltzman, Robert Smale, Yao-Shi Fu

Springerplus· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Farletuzumab in lung cancer.
Anish Thomas, Julia Maltzman, Raffit Hassan

Lung Cancer· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
Daniel C Christoph, Bernadette Reyna Asuncion, Biftu Hassan, Cindy Tran, Julia D Maltzman

J Thorac Oncol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis